Glenmark reaches $29m settlement with US states in generic drug antitrust case
( July 15, 2026, 18:35 GMT | Official Statement) -- MLex Summary: Glenmark Pharmaceuticals reached a $29 million settlement with a coalition of 49 attorneys general to resolve claims that it conspired to artificially inflate generic drug prices and reduce competition, New York Attorney General Letitia James announced. “Affordable generic drugs are a lifeline for New Yorkers with heart conditions, diabetes, and a range of other chronic illnesses,” James said. “Glenmark and other companies worked behind the scenes to boost their profits by illegally coordinating to raise drug prices, and now we are getting justice for the consumers who were harmed. I urge any New Yorker who may have been cheated by this scheme to find out if they are eligible for restitution and claim the money they are owed.”Statement follows in full. Also see attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.